...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What's going on with the Phase 2 ZEN-3694 mCRPC trial?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Based on the Feb 2019 presentation the bleed rate is $2mm/qtr or approx $700m/month so this funding seems to provide 3+ months of funding. I'm not sure if the Feb presentation includes the TNBC trial costs. Good to get the money but seems like they need much more.

Toinv

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply